According to the Forum of International Respiratory Societies, around 65 million individuals worldwide suffer from moderate to severe chronic obstructive pulmonary disease (COPD), with about 3 million dying each year, making it the world's third-biggest cause of mortality. Lung cancer is the most frequent deadly neoplasm worldwide, killing 1.6 million people yearly. Thus, respiratory diseases make up five of the 30 most common causes of death worldwide. The rise in respiratory disorders will require efficient and safe treatment methods for treating various respiratory disorders.
Access Full Report @ https://www.databridgemarketresearch.com/reports/global-plasma-fractionational-market
The Global Plasma Fractionation Market is expected to reach USD 40,088.69 million by 2028 from USD 24,432.02 million in 2020, growing with a substantial CAGR of 6.5% in the forecast period of 2021 to 2028. With the global frequency of 17%, anemia might affect up to 15 million older people in the European Union and North America. In both hospital inpatients and outpatients, the prevalence rises with age, reaching approximately 50% in men over the age of 80. Furthermore, due to an aging population in Western nations and outpatients, the number of anemic patients is expected to rise considerably in the coming years. Blood transfusions are considered the first and most effective option for treating elderly patients with severe, symptomatic anemia.
An increase in rare diseases that requires use of plasma therapy or plasma derivative across the world will drive the market's growth rate
Plasma contains hundreds of proteins that perform vital tasks in the human body, such as antibodies that fight illnesses and clotting factors that keep blood flowing. Plasma protein treatments are biological medication that replaces a person missing or functionally damaged proteins to cure plasma protein deficits. Rare diseases are also get treated using plasma therapies. Moreover, plasma-derived treatments are among the safest biological medicines available, with every aspect of their clinical use and supply chain carefully monitored in developed countries. Thus, with an increase in rare diseases, there would be greater emphasis on using plasma-based therapeutics, which is expected to drive the global plasma fractionation market.
Report Scope and Market Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2021 to 2028
|
|
Base Year
|
2020
|
|
Historic Years
|
2019 (Customizable to 2013 - 2018)
|
|
Quantitative Units
|
Revenue in USD Million, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
Product Type (Immunoglobulins, Coagulation Factor Concentrates, Albumin, Protease Inhibitors and Other Products), Application (Neurology, Immunology, Hematology, Critical Care, Pulmonology, Hemato- Oncology, Rheumatology and Others), Processing Technology (Ion- Exchange Chromatography , Affinity Chromatography, Cryopreservation, Ultrafiltration and Microfiltration), Mode (Modern Plasma Fractionation and Traditional Plasma Fractionation), End User (Hospitals & Clinics, Clinical Research Laboratories Academic Institutions and Others), Distribution Channel (Direct Tenders, Third Party Distribution and Others)
|
|
Countries Covered
|
U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America
|
|
Market Players Covered
|
Grifols, S.A. (Spain), Takeda Pharmaceutical Company Limited (Japan), Octapharma AG (Switzerland), CSL Plasma (U.S.), Japan Blood Products Organization (Japan), China Biologic Products Holdings, Inc. (China), Shanghai RAAS (China), Baxter (U.S.), Bio Products Laboratory Ltd. (U.S.), Pall Corporation (U.S.), Sichuan Yuanda Shuyang Pharmaceutical Co., Ltd. (China), Bharat Serums and Vaccines Limited (India), Merck KGaA (Germany), and Intas Pharmaceuticals Ltd. (India) among others
|
|
Data Points Covered in the Report
|
In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario, the market report curated by the Data Bridge Market Research team includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework
|
Segment Analysis:
Global plasma fractionation market is segmented into six notable segments which are based on the product type, application, processing technology, mode, end user and distribution channel.
- On the basis of product type, the plasma fractionation market is segmented into immunoglobulins, coagulation factor concentrates, albumin, protease inhibitors and other products. In 2020, immunoglobulins segment is expected to dominate the plasma fractionation market with 44.68% market share owing to the factors such as the high number of health benefits associated with immunomodulatory actions.
- On the basis of application, the plasma fractionation market is segmented into neurology, immunology, hematology, critical care, pulmonology, hemato-oncology, rheumatology and other applications. In 2020, the immunology segment is expected to dominate the plasma fractionation market with a 26.20% market share owing to the increasing usage of plasma proteins in treating immune deficiencies.
- On the basis of processing technology, the plasma fractionation market is segmented into ion-exchange chromatography, affinity chromatography, cryoprecipitation, ultrafiltration and microfiltration. In 2020, ion-exchange chromatography segment is expected to dominate the plasma fractionation market with 29.10% market share owing to the factor such as the high purification capability using ions by removing inorganic substances.
- On the basis of mode, the plasma fractionation market is segmented into modern plasma fractionation and traditional plasma fractionation. In 2020, modern plasma fractionation segment is expected to dominate the plasma fractionation market with 71.26% market share owing to the factors such as employing the state of art equipment and production facilities for the plasma fractionation process.
- On the basis of end user, the plasma fractionation market is segmented into hospitals & clinics, clinical research laboratories, academic institutes and others. In 2020, hospitals & clinics segment is expected to dominate the plasma fractionation market with 62.75% market share due to improving infrastructure and health care facilities provided by hospitals, along with increasing off- label use of plasma fractionated products in hospitals to treat various diseases.
Hospitals segment will dominate the end user segment of the plasma fractionation market
Hospitals will emerge as the dominating segment under distribution channel in 2021 with approximately 38% market share. This is because of the growing number of hospitals in the market especially in the developing economies. Further, growth and expansion of the healthcare industry all around the globe will further bolster the growth of this segment.
- On the basis of distribution channel, the plasma fractionation market is segmented into direct tenders, third party distribution and others. In 2020, direct tenders segment is expected to dominate the plasma fractionation market with 44.60% market share due to increasing distribution through direct tenders from the manufacturers to the health care workers.
Direct tenders segment will dominate the distribution channel segment of the plasma fractionation market
The direct tenders segment will emerge as the dominating segment under distribution channel in 2021. This is because of the growing number of direct tenders in the market especially in the developing economies. Further, growth and expansion of the distribution channels all around the globe will further bolster the growth of this segment.
Major Players
Data Bridge Market Research recognizes the following companies as the market players in market: Grifols, S.A. (Spain), Takeda Pharmaceutical Company Limited (Japan), Octapharma AG (Switzerland), CSL Plasma (U.S.), Japan Blood Products Organization (Japan), China Biologic Products Holdings, Inc. (China), Shanghai RAAS (China), Baxter (U.S.), Bio Products Laboratory Ltd. (U.S.), Pall Corporation (U.S.), Sichuan Yuanda Shuyang Pharmaceutical Co., Ltd. (China), Bharat Serums and Vaccines Limited (India), Merck KGaA (Germany), and Intas Pharmaceuticals Ltd. (India).
Market Development
- Kedrion Biopharma (Italy) began developing a plasma-derived medication for COVID-19 in August 2020 with the goal of making it accessible to patients in three to six months. The business collaborated closely with medical facilities from some of Italy's most COVID-infected regions.
- Octapharma AG (Switzerland) established a specific project team in April 2020 to look into potential novel treatments for COVID-19. Additionally, the business collaborated with other pioneers in plasma fractionation to create a potential plasma-derived hyperimmune immunoglobulin therapy for COVID-19.
- For its study on plasma therapy for COVID-19 patients, Virchow Biotech Pvt Ltd (India) received funding support from the Department of Biotechnology (DBT) National Biopharma Mission in April 2020. The business has suggested using many human convalescent donors to gather plasma.
Regional Analysis
Geographically, the countries covered in the market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
As per Data Bridge Market Research analysis:
North America is the dominant region in plasma fractionation market during the forecast period 2021 to 2028
North America dominates the advanced wound care market because of the growing adoption of advanced technology, increasing incidences of usage of plasma fractionated products and increasing innovative product developments.
Asia-Pacific is estimated to be the fastest-growing region in plasma fractionation market the forecast period 2021 to 2028
Asia-Pacific is expected to grow during the forecast period due to the increase in public and private funding for research and development, increased use of immunoglobulins, and rising prevalence of target diseases
COVID-19 Impact
Since there are no licenced medicines for COVID-19, caused by the new coronavirus SARS-CoV-2, treatment is currently mostly restricted to general supportive care. Plasma treatment is being used in many nations to treat COVID-19. Injecting the patient with convalescent sera from patients who have recently recovered from the COVID-19 infection is known as convalescent plasma therapy. Individuals who have been cured of COVID-19 have serum that contains virus-neutralizing antibodies that can function as passive antibody treatment. The COVID-19 convalescent sera is what it is known as. There are two approaches to obtain these convalescent sera: I through ordinary blood withdrawal followed by centrifugation; and (ii) with an apheresis machine/cell separator machine.
For more detailed information about the plasma fractionation market, visit: https://www.databridgemarketresearch.com/reports/global-plasma-fractionational-market
